Optimizing Multidisciplinary Care of Patients with Hidradenitis Suppurativa

Psoriasis received the second-most funding of any pediatric dermatology condition, even though it ranked fifth in terms of disease burden.

Patients reported quality-of-life benefits from treatment for nonsegmental vitiligo, even when clinical improvement started slowly.

Pediatric dermatology faces access disparities due to lack of awareness, language barriers, and training gaps in recognizing diverse skin conditions.

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.

Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.

The efficacy and safety of both approved and investigational drugs for moderate to severe hidradenitis suppurativa offer valuable evidence to guide clinical decision-making in a field where head-to-head trials are largely absent.